Abstract 177P
Background
Stomach cancer (SC) ranks as the 3rd leading cause of death among all cancer-related fatalities in the South Asia (SA) region. The complex interplay of cultural, lifestyle, and demographic factors in SA compounds the challenge to public health posed by the significant burden of stomach cancer.
Methods
Using the Global Burden of Disease framework, this study examined deaths and disability-adjusted life years (DALYs) attributed to SC caused by smoking by age, sex, and year across the 5 countries of the SA region from 1990-2019. Additionally, projections for the number of deaths up to 2040 were derived through regression analysis.
Results
The total count of deaths attributed to SC due to smoking witnessed an increase from 6,948 (95%UI: 4,963-8,890) in 1990 to 9,353 (95%UI: 6,632-12,325) in 2019. Concurrently, DALYs rose from 177,675 (95%UI: 124,165-232,327) in 1990 to 222,290 (95%UI: 149,831-299,787) in 2019. Assessing the annual percentage of change (APC), the Age-Standardized Mortality Rate (ASMR) experienced a decline of 49% from 1990-2019. Among the SA countries, Nepal exhibited the highest APC increase in total deaths at 76%, followed by Bhutan at 73%, India at 40%, Pakistan at 20%, and Bangladesh at 13% from 1990-2019. Conversely, the APC increase in DALYs was greatest in Nepal at 51%, while Bangladesh reported the lowest increase at 3% during the same period. Notably, the age group of 65-69 years recorded the highest number of deaths (1,555), while the age group of 60-64 years experienced the highest DALYs (37,194) in 2019. In terms of gender disparities, males bore a higher burden of stomach cancer attributable to smoking compared to females over the past three decades. The study's projections indicate an estimated 3,952 deaths (95%UI: 2,036-6,347) by the year 2040.
Conclusions
While notable advancements have been made in the management of SC, the burden attributed to smoking continues to rise over the last 3 decades. This accounts for 9.44% of deaths among the overall causes of SC-related fatalities. It emphasizes the importance of comprehensive tobacco control strategies to mitigate this burden, considering the diverse social, economic, and cultural factors unique to the region.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract